Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.

Dumortier M, Ladam F, Damour I, Vacher S, Bièche I, Marchand N, de Launoit Y, Tulasne D, Chotteau-Lelièvre A.

Breast Cancer Res. 2018 Jul 11;20(1):73. doi: 10.1186/s13058-018-0992-0.

2.

The iron chelator deferasirox synergizes with chemotherapy to treat triple negative breast cancers.

Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, de la Grange P, Schnitzler A, Lallemand F, Marangoni E, Bièche I, Callens C.

J Pathol. 2018 Jun 7. doi: 10.1002/path.5104. [Epub ahead of print]

PMID:
29876931
3.

The trimeric coiled-coil HSBP1 protein promotes WASH complex assembly at centrosomes.

Visweshwaran SP, Thomason PA, Guerois R, Vacher S, Denisov EV, Tashireva LA, Lomakina ME, Lazennec-Schurdevin C, Lakisic G, Lilla S, Molinie N, Henriot V, Mechulam Y, Alexandrova AY, Cherdyntseva NV, Bièche I, Schmitt E, Insall RH, Gautreau A.

EMBO J. 2018 Jul 2;37(13). pii: e97706. doi: 10.15252/embj.201797706. Epub 2018 May 29.

PMID:
29844016
4.

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences.

Cacheux W, Tsantoulis P, Briaux A, Vacher S, Mariani P, Richard-Molard M, Buecher B, Richon S, Jeannot E, Lazartigues J, Rouleau E, Mariani O, El Alam E, Cros J, Roman-Roman S, Mitry E, Girard E, Dangles-Marie V, Lièvre A, Bièche I.

Cancer Med. 2018 May 26. doi: 10.1002/cam4.1533. [Epub ahead of print]

5.

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Spasojevic C, Marangoni E, Vacher S, Assayag F, Meseure D, Château-Joubert S, Humbert M, Karam M, Ricort JM, Auclair C, Regairaz M, Bièche I.

Oncotarget. 2018 May 1;9(33):23208-23219. doi: 10.18632/oncotarget.25292. eCollection 2018 May 1.

6.

Involvement of the FOXO6 transcriptional factor in breast carcinogenesis.

Lallemand F, Petitalot A, Vacher S, de Koning L, Taouis K, Lopez BS, Zinn-Justin S, Dalla-Venezia N, Chemlali W, Schnitzler A, Lidereau R, Bieche I, Caputo SM.

Oncotarget. 2017 Dec 30;9(7):7464-7475. doi: 10.18632/oncotarget.23779. eCollection 2018 Jan 26.

7.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

PMID:
29463559
8.

Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.

Cacheux W, Dangles-Marie V, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Farkhondeh F, Mariani O, Rio-Frio T, Roman-Roman S, Mitry E, Bieche I, Lièvre A.

Oncotarget. 2017 Dec 8;9(1):464-476. doi: 10.18632/oncotarget.23066. eCollection 2018 Jan 2.

9.

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.

Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I.

Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11.

PMID:
29331751
10.

High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism.

Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M.

PLoS One. 2018 Jan 10;13(1):e0190619. doi: 10.1371/journal.pone.0190619. eCollection 2018.

11.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

PMID:
29147616
12.

Comparative Genomics of Bacillus amyloliquefaciens Strains Reveals a Core Genome with Traits for Habitat Adaptation and a Secondary Metabolites Rich Accessory Genome.

Belbahri L, Chenari Bouket A, Rekik I, Alenezi FN, Vallat A, Luptakova L, Petrovova E, Oszako T, Cherrad S, Vacher S, Rateb ME.

Front Microbiol. 2017 Aug 3;8:1438. doi: 10.3389/fmicb.2017.01438. eCollection 2017.

13.

Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2.

Weiswald LB, Hasan MR, Wong JCT, Pasiliao CC, Rahman M, Ren J, Yin Y, Gusscott S, Vacher S, Weng AP, Kennecke HF, Bièche I, Schaeffer DF, Yapp DT, Tai IT.

Mol Cancer Ther. 2017 Oct;16(10):2292-2303. doi: 10.1158/1535-7163.MCT-16-0666. Epub 2017 Jun 29.

PMID:
28663269
14.

Exposure of marine mussels to diclofenac: modulation of prostaglandin biosynthesis.

Courant F, Arpin-Pont L, Bonnefille B, Vacher S, Picot-Groz M, Gomez E, Fenet H.

Environ Sci Pollut Res Int. 2018 Mar;25(7):6087-6094. doi: 10.1007/s11356-017-9228-6. Epub 2017 May 21.

PMID:
28528506
15.

Clinical value of R-spondins in triple-negative and metaplastic breast cancers.

Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I.

Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.

16.

Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.

Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G.

Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.

PMID:
28291636
17.

Alterations in the balance of tubulin glycylation and glutamylation in photoreceptors leads to retinal degeneration.

Bosch Grau M, Masson C, Gadadhar S, Rocha C, Tort O, Marques Sousa P, Vacher S, Bieche I, Janke C.

J Cell Sci. 2017 Mar 1;130(5):938-949. doi: 10.1242/jcs.199091. Epub 2017 Jan 19.

18.

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.

Tury S, Becette V, Assayag F, Vacher S, Benoist C, Kamal M, Marangoni E, Bièche I, Lerebours F, Callens C.

Oncotarget. 2016 Dec 20;7(51):85124-85141. doi: 10.18632/oncotarget.13200.

19.

Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk.

Chakhtoura Z, Laki F, Bernadet M, Cherifi I, Chiche A, Pigat N, Bernichtein S, Courtillot C, Boutillon F, Bièche I, Vacher S, Tanguy ML, Bissery A, Grouthier V, Camparo P, Foretz M, Do Cruzeiro M, Pierre R, Rakotozafy F, Tichet J, Tejedor I, Guidotti JE, Sigal-Zafrani B, Goffin V, Touraine P.

J Clin Endocrinol Metab. 2016 Nov;101(11):4449-4460. Epub 2016 Aug 30.

PMID:
27575941
20.

MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.

Laé M, Gardrat S, Rondeau S, Richardot C, Caly M, Chemlali W, Vacher S, Couturier J, Mariani O, Terrier P, Bièche I.

Oncotarget. 2016 Dec 20;7(51):84428-84438. doi: 10.18632/oncotarget.12991.

21.

Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts.

Assayag F, Nicolas A, Vacher S, Dehainault C, Bieche I, Meseure D, Aerts I, Cassoux N, Houdayer C, Doz F, Decaudin D.

Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4916-4926. doi: 10.1167/iovs.15-18725.

PMID:
27654418
22.

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.

Deniziaut G, Tille JC, Bidard FC, Vacher S, Schnitzler A, Chemlali W, Trémoulet L, Fuhrmann L, Cottu P, Rouzier R, Bièche I, Vincent-Salomon A.

Oncotarget. 2016 Nov 8;7(45):73337-73346. doi: 10.18632/oncotarget.11819.

23.

Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer.

Mameri H, Bièche I, Meseure D, Marangoni E, Buhagiar-Labarchède G, Nicolas A, Vacher S, Onclercq-Delic R, Rajapakse V, Varma S, Reinhold WC, Pommier Y, Amor-Guéret M.

Clin Cancer Res. 2017 Apr 15;23(8):2116-2126. doi: 10.1158/1078-0432.CCR-16-0626. Epub 2016 Sep 6.

24.

Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.

Meseure D, Vacher S, Drak Alsibai K, Trassard M, Nicolas A, Leclere R, Lerebours F, Guinebretiere JM, Marangoni E, Lidereau R, Bieche I.

Cancer Microenviron. 2016 Dec;9(2-3):107-118. doi: 10.1007/s12307-016-0186-1. Epub 2016 Jul 9.

25.

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.

Hatem R, El Botty R, Chateau-Joubert S, Servely JL, Labiod D, de Plater L, Assayag F, Coussy F, Callens C, Vacher S, Reyal F, Cosulich S, Diéras V, Bièche I, Marangoni E.

Oncotarget. 2016 Jul 26;7(30):48206-48219. doi: 10.18632/oncotarget.10195.

26.

Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.

Sablin MP, Dubot C, Klijanienko J, Vacher S, Ouafi L, Chemlali W, Caly M, Sastre-Garau X, Lappartient E, Mariani O, Rodriguez J, Jouffroy T, Girod A, Calugaru V, Hoffmann C, Lidereau R, Berger F, Kamal M, Bieche I, Le Tourneau C.

Oncotarget. 2016 Jul 26;7(30):47418-47430. doi: 10.18632/oncotarget.10163.

27.

Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.

Meseure D, Vacher S, Lallemand F, Alsibai KD, Hatem R, Chemlali W, Nicolas A, De Koning L, Pasmant E, Callens C, Lidereau R, Morillon A, Bieche I.

Br J Cancer. 2016 Jun 14;114(12):1395-404. doi: 10.1038/bjc.2016.123. Epub 2016 May 12.

28.

Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value.

Meseure D, Vacher S, Alsibai KD, Nicolas A, Chemlali W, Caly M, Lidereau R, Pasmant E, Callens C, Bieche I.

Mol Cancer Res. 2016 Jul;14(7):623-33. doi: 10.1158/1541-7786.MCR-15-0418. Epub 2016 Apr 21.

29.

CAG repeat size in Huntingtin alleles is associated with cancer prognosis.

Thion MS, Tézenas du Montcel S, Golmard JL, Vacher S, Barjhoux L, Sornin V, Cazeneuve C, Bièche I, Sinilnikova O, Stoppa-Lyonnet D, Durr A, Humbert S.

Eur J Hum Genet. 2016 Aug;24(9):1310-5. doi: 10.1038/ejhg.2016.13. Epub 2016 Mar 16.

30.

Arpin downregulation in breast cancer is associated with poor prognosis.

Lomakina ME, Lallemand F, Vacher S, Molinie N, Dang I, Cacheux W, Chipysheva TA, Ermilova VD, de Koning L, Dubois T, Bièche I, Alexandrova AY, Gautreau A.

Br J Cancer. 2016 Mar 1;114(5):545-53. doi: 10.1038/bjc.2016.18. Epub 2016 Feb 11.

31.

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.

Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E.

Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22.

32.

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Hatem R, Labiod D, Château-Joubert S, de Plater L, El Botty R, Vacher S, Bonin F, Servely JL, Dieras V, Bièche I, Marangoni E.

Int J Cancer. 2016 May 15;138(10):2510-21. doi: 10.1002/ijc.29974. Epub 2016 Jan 6.

33.

Implication de la voie PD1/PDL1 et de la voie CTLA4/CD80 dans les tumeurs urothéliales.

Pignot G, Le Goux C, Bieche I, Vacher S, Barry de Longchamps N, Sibony M, Zerbib M.

Prog Urol. 2015 Nov;25(13):762. doi: 10.1016/j.purol.2015.08.096. French. No abstract available.

PMID:
26544291
34.

IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production.

Escobar P, Bouclier C, Serret J, Bièche I, Brigitte M, Caicedo A, Sanchez E, Vacher S, Vignais ML, Bourin P, Geneviève D, Molina F, Jorgensen C, Lazennec G.

Oncotarget. 2015 Oct 6;6(30):29034-47. doi: 10.18632/oncotarget.4732.

35.

Unraveling the Role of Huntingtin in Breast Cancer Metastasis.

Thion MS, McGuire JR, Sousa CM, Fuhrmann L, Fitamant J, Leboucher S, Vacher S, du Montcel ST, Bièche I, Bernet A, Mehlen P, Vincent-Salomon A, Humbert S.

J Natl Cancer Inst. 2015 Aug 20;107(10). pii: djv208. doi: 10.1093/jnci/djv208. Print 2015 Oct.

PMID:
26293574
36.

Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.

Chiker S, Pennaneach V, Loew D, Dingli F, Biard D, Cordelières FP, Gemble S, Vacher S, Bieche I, Hall J, Fernet M.

Cell Cycle. 2015;14(19):3066-78. doi: 10.1080/15384101.2015.1078020.

37.

MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics.

Di Benedetto M, Toullec A, Buteau-Lozano H, Abdelkarim M, Vacher S, Velasco G, Christofari M, Pocard M, Bieche I, Perrot-Applanat M.

Br J Cancer. 2015 Sep 1;113(5):773-85. doi: 10.1038/bjc.2015.267. Epub 2015 Jul 21.

38.

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?

Cizeron-Clairac G, Lallemand F, Vacher S, Lidereau R, Bieche I, Callens C.

BMC Cancer. 2015 Jul 5;15:499. doi: 10.1186/s12885-015-1505-5.

39.

p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.

Lodillinsky C, Infante E, Guichard A, Chaligné R, Fuhrmann L, Cyrta J, Irondelle M, Lagoutte E, Vacher S, Bonsang-Kitzis H, Glukhova M, Reyal F, Bièche I, Vincent-Salomon A, Chavrier P.

Oncogene. 2016 Jan 21;35(3):344-57. doi: 10.1038/onc.2015.87. Epub 2015 Apr 20.

PMID:
25893299
40.

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.

Rondeau S, Vacher S, De Koning L, Briaux A, Schnitzler A, Chemlali W, Callens C, Lidereau R, Bièche I.

Br J Cancer. 2015 Mar 17;112(6):1059-66. doi: 10.1038/bjc.2015.60.

41.

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

Nunes M, Vrignaud P, Vacher S, Richon S, Lièvre A, Cacheux W, Weiswald LB, Massonnet G, Chateau-Joubert S, Nicolas A, Dib C, Zhang W, Watters J, Bergstrom D, Roman-Roman S, Bièche I, Dangles-Marie V.

Cancer Res. 2015 Apr 15;75(8):1560-6. doi: 10.1158/0008-5472.CAN-14-1590. Epub 2015 Feb 24.

42.

Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.

de Plater L, Vincent-Salomon A, Berger F, Nicolas A, Vacher S, Gravier E, Thuleau A, Karboul N, Richardson M, Elbaz C, Marangoni E, Bièche I, Paoletti X, Roman-Roman S, Culp PA, Asselain B, Diéras V, Decaudin D.

PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014.

43.

Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.

Karam M, Bièche I, Legay C, Vacher S, Auclair C, Ricort JM.

J Cell Mol Med. 2014 Dec;18(12):2536-52. doi: 10.1111/jcmm.12322. Epub 2014 Oct 7.

44.

Tubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon.

Rocha C, Papon L, Cacheux W, Marques Sousa P, Lascano V, Tort O, Giordano T, Vacher S, Lemmers B, Mariani P, Meseure D, Medema JP, Bièche I, Hahne M, Janke C.

EMBO J. 2014 Oct 1;33(19):2247-60. doi: 10.15252/embj.201488466. Epub 2014 Sep 1. Erratum in: EMBO J. 2014 Nov 18;33(22):2735.

45.

Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.

Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E.

Clin Cancer Res. 2014 Aug 15;20(16):4314-25. doi: 10.1158/1078-0432.CCR-13-3230. Epub 2014 Jun 19.

46.

Control of MT1-MMP transport by atypical PKC during breast-cancer progression.

Rossé C, Lodillinsky C, Fuhrmann L, Nourieh M, Monteiro P, Irondelle M, Lagoutte E, Vacher S, Waharte F, Paul-Gilloteaux P, Romao M, Sengmanivong L, Linch M, van Lint J, Raposo G, Vincent-Salomon A, Bièche I, Parker PJ, Chavrier P.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):E1872-9. doi: 10.1073/pnas.1400749111. Epub 2014 Apr 21.

47.

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings.

Bieche I, Vacher S, Vallerand D, Richon S, Hatem R, De Plater L, Dahmani A, Némati F, Angevin E, Marangoni E, Roman-Roman S, Decaudin D, Dangles-Marie V.

BMC Cancer. 2014 Mar 13;14:178. doi: 10.1186/1471-2407-14-178.

48.

PIK3R1 underexpression is an independent prognostic marker in breast cancer.

Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D, Callens C, Rouleau E, Spyratos F, Lidereau R, Bièche I.

BMC Cancer. 2013 Nov 14;13:545. doi: 10.1186/1471-2407-13-545.

49.

Inhibitory signalling to the Arp2/3 complex steers cell migration.

Dang I, Gorelik R, Sousa-Blin C, Derivery E, Guérin C, Linkner J, Nemethova M, Dumortier JG, Giger FA, Chipysheva TA, Ermilova VD, Vacher S, Campanacci V, Herrada I, Planson AG, Fetics S, Henriot V, David V, Oguievetskaia K, Lakisic G, Pierre F, Steffen A, Boyreau A, Peyriéras N, Rottner K, Zinn-Justin S, Cherfils J, Bièche I, Alexandrova AY, David NB, Small JV, Faix J, Blanchoin L, Gautreau A.

Nature. 2013 Nov 14;503(7475):281-4. doi: 10.1038/nature12611. Epub 2013 Oct 16.

PMID:
24132237
50.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

Supplemental Content

Loading ...
Support Center